| Literature DB >> 30153112 |
Man Lung Yeung1,2,3,4, Lilong Jia2, Cyril C Y Yip1,2,3,4, Jasper F W Chan1,2,3,4, Jade L L Teng2, Kwok-Hung Chan2, Jian-Piao Cai2, Chaoyu Zhang2, Anna J Zhang1,2,3,4, Wan-Man Wong2, Kin-Hang Kok2, Susanna K P Lau1,2,3,4, Patrick C Y Woo1,2,3,4, Janice Y C Lo5, Dong-Yan Jin6, Shin-Ru Shih7,8, Kwok-Yung Yuen1,2,3,4,9,10.
Abstract
Enterovirus A71 (EV-A71) receptors that have been identified to date cannot fully explain the pathogenesis of EV-A71, which is an important global cause of hand, foot, and mouth disease and life-threatening encephalitis. We identified an IFN-γ-inducible EV-A71 cellular entry factor, human tryptophanyl-tRNA synthetase (hWARS), using genome-wide RNAi library screening. The importance of hWARS in mediating virus entry and infectivity was confirmed by virus attachment, in vitro pulldown, antibody/antigen blocking, and CRISPR/Cas9-mediated deletion. Hyperexpression and plasma membrane translocation of hWARS were observed in IFN-γ-treated semipermissive (human neuronal NT2) and cDNA-transfected nonpermissive (mouse fibroblast L929) cells, resulting in their sensitization to EV-A71 infection. Our hWARS-transduced mouse infection model showed pathological changes similar to those seen in patients with severe EV-A71 infection. Expression of hWARS is also required for productive infection by other human enteroviruses, including the clinically important coxsackievirus A16 (CV-A16) and EV-D68. This is the first report to our knowledge on the discovery of an entry factor, hWARS, that can be induced by IFN-γ for EV-A71 infection. Given that we detected high levels of IFN-γ in patients with severe EV-A71 infection, our findings extend the knowledge of the pathogenicity of EV-A71 in relation to entry factor expression upon IFN-γ stimulation and the therapeutic options for treating severe EV-A71-associated complications.Entities:
Keywords: Infectious disease; Microbiology; Molecular pathology
Mesh:
Substances:
Year: 2018 PMID: 30153112 PMCID: PMC6205371 DOI: 10.1172/JCI99411
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808